5-甲基-2-(三氟甲基)呋喃-3-羧胺 | 175276-68-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃
• 中文名称: 5-甲基-2-(三氟甲基)呋喃-3-羧胺
• 英文名称: 5-methyl-2-(trifluoromethyl)furan-3-carboxamide
• CAS: 175276-68-3
• 化学式: C₇H₆F₃NO₂
• mdl: MFCD00276988
• 分子量: 193.125
• InChiKey: NXCKENOPYUWPSU-UHFFFAOYSA-N

物化性质

• 熔点：
  120-123°C
• 沸点：
  205.0±40.0 °C(Predicted)
• 密度：
  1.372±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.285
• 拓扑面积：
  56.2
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S24/25
• 危险类别码：
  R36/37/38

反应信息

• 作为反应物：
  描述：

  5-甲基-2-(三氟甲基)呋喃-3-羧胺 在 五氯化磷 作用下， 以 四氯化碳 为溶剂， 反应 2.5h， 以62%的产率得到5-methyl-2-(trifluoromethyl)-3-cyanofuran
  参考文献：
  名称：

  Synthesis and Wittig Reaction of Formylated (Trifluoromethylfuryl)methanephosphonates

  摘要：

  Methods of synthesis of 4-functionalyzed (5-trifluoromethylfur-2-yl)methanephosphonates and (5-methyl-2-trifluoromethylfur-3-yl)methanephosphonate are developed. Their formylation with ethyl formate in the presence of sodium foil is studied. Spectral characteristics of tautomers of obtained derivatives of phosphonoacetic aldehyde are evaluated. It is shown that interaction of obtained formyl derivatives with ethoxycarbonylmethylenetriphenylphosphorane regardless of the structure of the furan fragment leads to 4-furylsubstituted alkyl 4-(diethoxyphosphoryl)but-3-enoate, the abnormal product of Wittig reaction.

  DOI：

  10.1134/s1070363218020093
• 作为产物：
  描述：

  5-甲基-2-（三氟甲基）呋喃-3-碳酰氯 在 氨 作用下， 以 水 、 苯 为溶剂， 反应 1.0h， 以68%的产率得到5-甲基-2-(三氟甲基)呋喃-3-羧胺
  参考文献：
  名称：

  Synthesis and Wittig Reaction of Formylated (Trifluoromethylfuryl)methanephosphonates

  摘要：

  Methods of synthesis of 4-functionalyzed (5-trifluoromethylfur-2-yl)methanephosphonates and (5-methyl-2-trifluoromethylfur-3-yl)methanephosphonate are developed. Their formylation with ethyl formate in the presence of sodium foil is studied. Spectral characteristics of tautomers of obtained derivatives of phosphonoacetic aldehyde are evaluated. It is shown that interaction of obtained formyl derivatives with ethoxycarbonylmethylenetriphenylphosphorane regardless of the structure of the furan fragment leads to 4-furylsubstituted alkyl 4-(diethoxyphosphoryl)but-3-enoate, the abnormal product of Wittig reaction.

  DOI：

  10.1134/s1070363218020093

文献信息

• [EN] 1- (2H-PYRAZOL -3-YL) -3YL) {4-`1- (BENZOYL) -PIPERIDIN-4-YLMETHYL!-PHENYL}-UREA DERIVATIVES AND RELATED COMPOUNDS AS INHBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF IMFLAMMATIONS<br/>[FR] DERIVES DE 1-(2H-PYRAZOL-3-YL)-3-{4-`1-(BENZOYL)-PIPERIDIN-4-YLMETHYL!-PHENYL}-UREE ET COMPOSES ASSOCIES UTILISES COMME INHIBITEURS DE LA KINASE P38 ET/OU COMME INHIBITEURS DU FACTEUR DE NECROSE TUMORALE (TNF) DANS LE TRAITEMENT DES INFLAMMATIONS
  申请人：AVENTIS PHARMA INC

  公开号：WO2004100946A1

  公开（公告）日：2004-11-25

  The present invention provides compounds of Formula (I) Wherein ( ) is an optional ethylene bridge; R1 is alkyl, cycloalkyl, aryl or aryl substituted with one or more substituents selected from alkyl, alkoxy and amino, or R1 is pyridyl or pyridyl substituted with one or more substituents selected from alkyl, alkoxy and amino; R2 is optionally substituted alkyl, alkoxyalkyl, optionally substituted cycloalkylalkyl, arylalkyl, or R2 is arylalkyl substituted with one or more substituents selected from alkyl, alkoxy; X is -C(O)-, -C(O)-CH2-, -S(O)2-, or NH-C(O)- ; and A is optionally substituted alkyl or other substituents as defined in claim 1. Pharmaceutical compositions comprising such compounds, their preparation, and their pharmaceutical use in the treatment of disease states capable of being modulated by the inhibition of p38 kinase and/or tumor necrosis factor (TNF), such as asthma or joint inflammation.

  本发明提供了Formula (I)的化合物，其中( )是可选的乙烯桥；R1是烷基、环烷基、芳基或芳基，其上取代基可为烷基、烷氧基和氨基中的一种或多种，或者R1是吡啶基或吡啶基，其上取代基可为烷基、烷氧基和氨基中的一种或多种；R2是可选取代的烷基、烷氧基烷基、可选取代的环烷基烷基、芳基烷基，或者R2是芳基烷基，其上取代基可为烷基、烷氧基中的一种或多种；X是-C(O)-、-C(O)-CH2-、-S(O)2-或NH-C(O)-；A是可选取代的烷基或其他在权利要求1中定义的取代基。包括这些化合物的药物组合物、其制备以及在治疗能够通过抑制p38激酶和/或肿瘤坏死因子(TNF)调节的疾病状态中的药用，如哮喘或关节炎。
• Cathepsin C Inhibitors
  申请人：DENG Jianghe

  公开号：US20090264499A1

  公开（公告）日：2009-10-22

  A compound of formula (IA) or (IB) and their use in treating inflammatory diseases such as COPD.

  化合物的公式（IA）或（IB）及其在治疗炎症性疾病如COPD中的用途。
• Novel potassium channels modulators
  申请人：Garcia Gabriel

  公开号：US20050070570A1

  公开（公告）日：2005-03-31

  The invention relates to compounds having the Formula (I) or a salt, or a physiologically functional derivative, or a prodrug thereof, wherein Z is carbonyl or sulfonyl; R 1 is alkyl, alkenyl, alkynyl, aryl, H, halogen, haloalkyl, haloalkoxy, hydroxyalkyl, cycloalkyl or heteroaryl; R 2 is H, OH, —CH 2 —SO 2 -alkyl, —CH 2 —SO 2 -cycloalkyl, —CH 2 —SO 2 -aryl, —CH 2 —SO 2 -heteroaryl, alkylamine, alkenylamine, alkynylamine, cycloalkylamine, arylamine, heteroarylamine, aryl, haloalkyl, haloalkoxy, hydroxyalkyl, cycloalkyl, heteroaryl or a linear or branched alkyl, alkenyl, alkynyl, which can optionally be substituted by one or more substituents R 3 ; R 3 is H, alkyl, alkenyl, alkynyl, cycloalkyl, —CO 2 R 4 , —CONHR 4 , —CONR 4 R 4 , —CR 4 O, —SO 2 R 4 , —NR 4 —CO—R 4 , alkoxy, alkylthio, —OH, —SH, —O-aryl, —O-cycloalkyl, —S-aryl, —S-cycloalkyl, hydroxyalkyl, halogen, haloalkyl, haloalkoxy, CN, NO 2 , hydroxyalkylamine, aminoalkyl, alkylamine, aryl or heteroaryl; R 4 is H, halogen, alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, alkylthio, —O-aryl, —O-cycloalkyl, OH, SH, —S-aryl, —S-cycloalkyl, hydroxyalkyl, haloalkyl, haloalkoxy, hydroxyalkyl-amine, aminoalkyl, alkylamine, aryl or heteroaryl; R 5 is alkyl, alkenyl or alkynyl.

  该发明涉及具有式（I）的化合物或其盐，或其生理功能衍生物，或其前药，其中Z为羰基或磺酰基；R1为烷基，烯烃基，炔烃基，芳基，氢，卤素，卤代烷基，卤代甲氧基，羟基烷基，环烷基或杂环芳基；R2为氢，羟基，—CH2—SO2-烷基，—CH2—SO2-环烷基，—CH2—SO2-芳基，—CH2—SO2-杂环芳基，烷基胺，烯烃基胺，炔烃基胺，环烷基胺，芳基胺，杂环芳基胺，芳基，卤代烷基，卤代甲氧基，羟基烷基，环烷基，杂环芳基或一个线性或支链烷基，烯烃基，炔烃基，可以选择地被一个或多个取代基R3取代；R3为氢，烷基，烯烃基，炔烃基，环烷基，—CO2R4，—CONHR4，—CONR4R4，—CR4O，—SO2R4，—NR4—CO—R4，烷氧基，烷基硫醚，—羟基，—硫氢，—O-芳基，—O-环烷基，—S-芳基，—S-环烷基，羟基烷基，卤素，卤代烷基，卤代甲氧基，CN，NO2，羟基烷胺，氨基烷基，烷基胺，芳基或杂环芳基；R4为氢，卤素，烷基，烯烃基，炔烃基，环烷基，烷氧基，烷基硫醚，—O-芳基，—O-环烷基，羟基，硫氢，—S-芳基，—S-环烷基，羟基烷基，卤代烷基，卤代甲氧基，羟基烷胺，氨基烷基，烷基胺，芳基或杂环芳基；R5为烷基，烯烃基或炔烃基。
• Novel heterocyclic NF-kB inhibitors
  申请人：Leban Johann

  公开号：US20060069102A1

  公开（公告）日：2006-03-30

  The present invention relates to compounds of the general formula (1) and salts and physiologically functional derivatives thereof, wherein R 1 is independently hydrogen; alkyl, cycloalkyl, hydroxyalkyl, haloalkyl, haloalkyloxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl or substituted arylalkyl; R 2 is independently —NR 3 R 4 , R 3 is independently alkyl, cycloalkyl, alkoxy, alkylamine, —OH, —SH, alkylthio, hydroxyalkyl, haloalkyl, haloalkyloxy, aryl or heteroaryl, R 4 is independently alkyl, cycloalkyl, alkoxy, alkylamine, alkylthio, hydroxyalkyl, haloalkyl, haloalkyloxy, aryl or heteroaryl; R 5 is independently H, COR 6 , CO 2 R 6 , SOR 6 , SO 3 R 6 , alkyl, cycloalkyl, alkoxy, —NH 2 , alkylamine, —NR 7 COR 6 , halogen, —OH, —SH, alkylthio, hydroxyalkyl, haloalkyl, haloalkyloxy, aryl or heteroaryl; R 6 is independently H, alkyl, cycloalkyl, —NH 2 , alkylamine, aryl or heteroaryl; R 7 is independently H, alkyl, cycloalkyl, alkoxy, —OH, —SH, alkylthio, hydroxyalkyl, aryl, or heteroaryl; p is 0, or 1; q is 0, or 1; X is CO, or SO 2 .

  本发明涉及一般式（1）的化合物及其盐和生理功能衍生物，其中R1独立地为氢；烷基，环烷基，羟基烷基，卤代烷基，卤代烷氧基，芳基，取代芳基，杂芳基，取代杂芳基，芳基烷基或取代芳基烷基；R2独立地为—NR3R4，R3独立地为烷基，环烷基，烷氧基，烷基胺，—OH，—SH，烷硫基，羟基烷基，卤代烷基，卤代烷氧基，芳基或杂芳基，R4独立地为烷基，环烷基，烷氧基，烷基胺，烷硫基，羟基烷基，卤代烷基，卤代烷氧基，芳基或杂芳基；R5独立地为H，COR6，CO2R6，SOR6，SO3R6，烷基，环烷基，烷氧基，—NH2，烷基胺，—NR7COR6，卤素，—OH，—SH，烷硫基，羟基烷基，卤代烷基，卤代烷氧基，芳基或杂芳基；R6独立地为H，烷基，环烷基，—NH2，烷基胺，芳基或杂芳基；R7独立地为H，烷基，环烷基，烷氧基，—OH，—SH，烷硫基，羟基烷基，芳基或杂芳基；p为0或1；q为0或1；X为CO或SO2。
• Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof
  申请人：Sekiguchi Yoshinori

  公开号：US20050197350A1

  公开（公告）日：2005-09-08

  The present invention relates to novel compounds of the Formula (I): which act as MCH receptor antagonists. These compositions are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.

  本发明涉及一种新的化合物，其化学式为(I)，该化合物作为MCH受体拮抗剂。这些组合物在制药组合物中的应用包括预防或治疗改善记忆功能、睡眠和觉醒、焦虑、抑郁、情绪障碍、癫痫、肥胖症、糖尿病、食欲和进食障碍、心血管疾病、高血压、血脂异常、心肌梗死、暴食症包括贪食症、厌食症、精神障碍包括躁郁症、精神分裂症、谵妄、痴呆、压力、认知障碍、注意力缺陷障碍、物质滥用障碍和运动障碍包括帕金森病、癫痫和成瘾等。